Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection

Talarico et al., NCT04385043, COV2-CP, NCT04385043, May 2021
Estimated 400 patient convalescent plasma late treatment RCT with results not reported over 5 years after estimated completion.
29 convalescent plasma RCTs have results missing long after expected1-29
The trials report a total of 3,534 patients, with 15 trials having actual enrollment of 1,143, and the remainder estimated.
Talarico et al., 15 May 2021, Randomized Controlled Trial, Italy, trial NCT04385043 (history) (COV2-CP). Contact: trasfusionale@aocz.it, longhini@unicz.it, f.zinno@aocs.it, centro.trasfusionale@asp.crotone.it, atrimarchi@aorc.it, trasfusionale@aspvv.it.
Late treatment
is less effective